News Novartis' CAR-T drug needs new payment model, says Express S... Cost of Novartis' revolutionary therapy is obstacle, says CMO.
News Gilead swoops to buy Kite for $12billion Gilead has sealed a deal to acquire cell therapy leader Kite for just under $12 billion.
News Real world data essential for CAR-T therapy success Innovators will need to quantify value to bring costly drugs to market.
News Scottish firm gets EU funding for 'off the shelf' cancer cel... First patients could be treated in 2019.
News Kite files CAR-T therapy in EU, ahead of Novartis rival Kite eyes possible CAR-T launch next year.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
